Form 4 for IBRX ImmunityBio, Inc.

Accepted 2021-09-13 00:00:00 ET · period of report 2021-09-09 · accession 0001209191-21-055786 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-09-13	2021-09-09	IBRX	Sachs David C.	CFO	M - OptEx	$0.00	+7,598	26.5K	+40%	$0
D	2021-09-13	2021-09-09	IBRX	Sachs David C.	CFO	M - OptEx	$0.00	-7,598	161.6K	-4%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-09-09	M	A	7,598	$0.00	26,458	D	—	—	(F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
2	Derivative	Restricted Stock Units	2021-09-09	M	D	7,598	$0.00	161,633	D	— · — to —	7,598 Common Stock	(F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) 17,242 of the restricted stock units ("RSUs") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026.